**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 77421

**Manuscript Type:** LETTER TO THE EDITOR

**Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis**

Gao FB *et al*. Thrombolysis for PVST

Fang-Bo Gao, Le Wang, Wen-Xiu Zhang, Xiao-Dong Shao, Xiao-Zhong Guo, Xing-Shun Qi

**Fang-Bo Gao, Le Wang, Wen-Xiu Zhang, Xiao-Dong Shao, Xiao-Zhong Guo, Xing-Shun Qi,** Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China

**Fang-Bo Gao,** Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning Province, China

**Author contributions:** Qi XS conceived this manuscript; Zhang WX, Guo XZ, and Qi XS treated this case; Gao FB, Wang L, and Qi XS followed this case; Gao FB and Qi XS drafted the manuscript; Gao FB, Wang L, Zhang WX, Shao XD, Guo XZ, and Qi XS revised the manuscript; all authors have made an intellectual contribution to the manuscript and approved the submission.

**Corresponding author: Xing-Shun Qi, MD, PhD, Associate Professor,** Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. xingshunqi@126.com

**Received:** April 29, 2022

**Revised:** June 1, 2022

**Accepted:** August 15, 2022

**Published online:** September 27, 2022

**Abstract**

Acute portal venous system thrombosis (PVST) can cause acute mesenteric ischemia and even intestinal infarction, which are potentially fatal, and requires recanalization in a timely fashion. Herein, we report a 56-year-old man with acute non-cirrhotic symptomatic extensive PVST who achieved portal vein recanalization after systemic thrombolysis combined with anticoagulation. Initially, anticoagulation with enoxaparin sodium for 4 d was ineffective, and then systemic thrombolysis for 7 d was added. After that, his abdominal pain completely disappeared, and portal vein system vessels became gradually patent. Long-term anticoagulation therapy was maintained. In conclusion, 7-d systemic thrombolysis may be an effective and safe choice of treatment for acute symptomatic extensive PVST which does not respond to anticoagulation therapy.

**Key Words:** Portal vein; Mesenteric vein; Thrombosis; Thrombolysis; Anticoagulation; Deep vein thrombosis

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Gao FB, Wang L, Zhang WX, Shao XD, Guo XZ, Qi XS. Successful treatment of acute symptomatic extensive portal venous system thrombosis by 7-day systemic thrombolysis. *World J Gastrointest Surg* 2022; 14(9): 1082-1085

**URL:** https://www.wjgnet.com/1948-9366/full/v14/i9/1082.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v14.i9.1082

**Core Tip:** The present case suggests that systemic thrombolysis should be safe and effective for acute extensive portal venous system thrombosis, if it is unresponsive to anticoagulation.

**TO THE EDITOR**

Acute portal venous system thrombosis (PVST) is potentially life-threatening and can achieve a good response to agitation thrombolysis combined with catheter-directed thrombolysis[1]. However, it should be acknowledged that systemic thrombolysis, a more convenient treatment approach, has been rarely attempted for the treatment of acute PVST in clinical practice due to its potential bleeding risk. Herein, we report a case of acute symptomatic extensive PVST successfully treated by systemic thrombolysis combined with anticoagulation to strengthen our confidence in its clinical efficacy and safety.

A 56-year-old man with a history of hepatitis B virus infection was admitted to the Department of Gastroenterology due to aggravating severe epigastric pain for nearly half a month. He had no other obvious medical history. On physical examinations, his abdomen was soft without abdominal tenderness, rebound, or tension. On day 1 of admission, laboratory tests were performed (Table 1). Contrast-enhanced computed tomography (CT) showed no contrast agent filling within all vessels of the portal venous system, including the main portal vein (MPV), right portal vein (RPV), left portal vein (LPV), confluence of the superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV (Figure 1A), suggesting a diagnosis of occlusive PVST. Thus, subcutaneous injection of enoxaparin sodium was immediately initiated at a dose of 5000 IU (62.5 IU/kg) twice daily. On day 5, his abdominal pain was not relieved. Anti-Xa level was 0.05 IU/mL (reference range: 0-0.1 IU/mL). Contrast-enhanced CT showed no significant improvement of PVST (Figure 1B). Thus, systemic thrombolysis was recommended. After obtaining this patient and his relatives’ informed consent, intravenous injection of urokinase at a dose of 300000 IU twice daily was added on subcutaneous injection of enoxaparin sodium at a dose of 5000 IU twice daily. On day 10, this patient's abdominal pain improved significantly. Contrast-enhanced CT showed that MPV, LPV, and RPV thromboses were partially recanalized (Figure 1C). On day 12, urokinase was discontinued. No bleeding event occurred during the period of systemic thrombolysis. On day 17, his abdominal pain completely disappeared. Then, he was discharged. Enoxaparin sodium was replaced with oral rivaroxaban 20 mg once daily. After 5-mo anticoagulation with rivaroxaban, contrast-enhanced CT showed that the SMV and SV became patent and fine collateral vessels developed around the RPV without signs of esophageal varices (Figure 1D). Laboratory tests were performed again (Table 1). At the time of writing this paper, rivaroxaban is still continued.

Anticoagulation is the preferred choice of treatment for acute PVST[2], but 18% of patients still develop transmural intestinal necrosis after anticoagulation therapy, and 25%-50% will develop pre-hepatic portal hypertension[3,4]. Patients with acute PVST who do not respond to anticoagulation therapy may benefit from thrombolytic therapy[5]. However, thrombolytic therapy has a higher risk of bleeding, including upper gastrointestinal bleeding, abdominal bleeding, and epistaxis. Notably, the current evidence on systemic thrombolytic therapy for PVST is scare. In a retrospective cohort study[6], 33 patients with acute PVST were treated with intravenous injection of 750000 IU/d streptokinase or 100-150 mg/6-12 h recombinant tissue-type plasminogen activator (rt-PA) for 2-3 d, followed with heparin infusion, and then received oral anticoagulants for 12 mo after discharge. Thrombosis recanalization was achieved in 23 patients. In a prospective cohort study[7], nine cirrhotic patients with recent PVST received continuous intravenous infusion of rt-PA at a dose of 0.25 mg/kg/d combined with subcutaneous injection of low molecular weight heparin for a maximum duration of 7 d. Thrombosis recanalization was achieved in eight patients. Besides, a stepwise thrombolysis regimen for PVST should be considered. In a study by Benmassaoud *et al*[8], 22 non-cirrhotic patients with acute PVST received systemic thrombolysis, of whom eight achieved portal vein recanalization, and the remaining 14 did not have any improvement of thrombosis or abdominal pain and were then treated with transjugular intrahepatic portosystemic shunt (TIPS) or local thrombolysis. Finally, the overall rate of portal vein recanalization was 86.4%. Notably, local thrombolysis and TIPS were employed in the study by Benmassaoud *et al*[8], but they are more invasive and technically complicated as compared to systemic thrombolysis. In our case, initial anticoagulation was less effective, and thus systemic thrombolysis was given. The symptoms improved significantly after thrombolysis, which avoided further vascular interventional procedures, and even surgery for intestinal infarction and necrosis[9].

Acute PVST is often defined if PVST develops 1-3 wk since the onset of symptoms. Accordingly, our case should be diagnosed with acute PVST. Notably, the timing of antithrombotic therapy for acute PVST is very important. A shorter interval from the diagnosis of PVST to initiation of antithrombotic therapy indicates a higher probability of thrombus recanalization[10]. In our case, the interval was relatively long, which potentially compromised the efficacy of anticoagulation and forced the use of systemic thrombolysis.

In conclusion, systemic thrombolysis should be considered in the cases where anticoagulant therapy fails and interventional therapy is neither available nor feasible. The timing of systemic thrombolytic therapy and the dose of thrombolytic drugs should be further explored.

**REFERENCES**

1 **Wang CY**, Wei LQ, Niu HZ, Gao WQ, Wang T, Chen SJ. Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. *World J Gastroenterol* 2018; **24**: 4482-4488 [PMID: 30357003 DOI: 10.3748/wjg.v24.i39.4482]

2 **Wang L**, Xu X, Hou Y, Shao X, Guo X, Qi X. Acute mesenteric vein thrombosis after endoscopic injection sclerotherapy for esophageal varices in a patient with liver cirrhosis. *Drug Discov Ther* 2019; **13**: 118-121 [PMID: 31080203 DOI: 10.5582/ddt.2019.01014]

3 **Plessier A**, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D; European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. *Hepatology* 2010; **51**: 210-218 [PMID: 19821530 DOI: 10.1002/hep.23259]

4 **Condat B**, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. *Hepatology* 2000; **32**: 466-470 [PMID: 10960436 DOI: 10.1053/jhep.2000.16597]

5 **Rössle M**, Bettinger D, Trebicka J, Klinger C, Praktiknjo M, Sturm L, Caca K, Mücke VT, Radecke K, Engelmann C, Zipprich A, Heinzow H, Meyer C, Tappe U, Appenrodt B, Schmidt A, Lange C, Strassburg C, Zeuzem S, Grandt D, Schmidt H, Moessner J, Berg T, Lammert F, Thimme R, Schultheiß M. A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. *Aliment Pharmacol Ther* 2020; **52**: 329-339 [PMID: 32506456 DOI: 10.1111/apt.15811]

6 **Malkowski P**, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E, Krawczyk M. Thrombolytic treatment of portal thrombosis. *Hepatogastroenterology* 2003; **50**: 2098-2100 [PMID: 14696472]

7 **De Santis A**, Moscatelli R, Catalano C, Iannetti A, Gigliotti F, Cristofari F, Trapani S, Attili AF. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. *Dig Liver Dis* 2010; **42**: 451-455 [PMID: 19819770 DOI: 10.1016/j.dld.2009.08.009]

8 **Benmassaoud A**, AlRubaiy L, Yu D, Chowdary P, Sekhar M, Parikh P, Finkel J, See TC, O'Beirne J, Leithead JA, Patch D. A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. *Aliment Pharmacol Ther* 2019; **50**: 1049-1058 [PMID: 31489698 DOI: 10.1111/apt.15479]

9 **Kumar S**, Sarr MG, Kamath PS. Mesenteric venous thrombosis. *N Engl J Med* 2001; **345**: 1683-1688 [PMID: 11759648 DOI: 10.1056/NEJMra010076]

10 **Wang L**, Guo X, Xu X, De Stefano V, Plessier A, Noronha Ferreira C, Qi X. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. *Adv Ther* 2021; **38**: 495-520 [PMID: 33155180 DOI: 10.1007/s12325-020-01550-4]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 29, 2022

**First decision:** May 29, 2022

**Article in press:** August 15, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Dasuqi SA, Saudi Arabia; El-Karaksy H, Egypt **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 Axial and coronal computed tomography images in this patient.** A: On day 1 of admission, computed tomography (CT) images demonstrated occlusive thrombosis within the main portal vein (MPV), left portal vein (LPV), right portal vein (RPV), confluence of the superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV, with fine collaterals around the hilum (red arrow); B: On day 5, CT images demonstrated partially recanalized LPV and RPV (red arrow); C: On day 10, CT images demonstrated partially recanalized MPV, LPV, and RPV (red arrow); D: After 5-mo anticoagulation with rivaroxaban, CT images demonstrated completely recanalized SMV and SV (red arrow).

**Table 1 Laboratory tests in this patient**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Laboratory tests** | **Reference range** | **Before antithrombotic treatment** | **After 7-d thrombolysis** | **After 5-mo oral anticoagulants** |
| White blood cell count (109/L) | 3.5-9.5 | 9.70 | 5.20 | 6.7 |
| Hemoglobin (g/L) | 130-175 | 143 | 119 | 164 |
| Platelet count (109/L) | 125-350 | 230 | 242 | 123 |
| Total bilirubin (μmol/L) | 5.1-22.2 | 16.70 | 8.1 | 13.9 |
| Aspartate aminotransferase (U/L) | 15-40 | 17.60 | 16.29 | 18.65 |
| Alanine aminotransferase (U/L) | 9-50 | 20.39 | 20 | 21.99 |
| International normalized ratio | 0.9-1.2 | 1.19 | 1.15 | 0.99 |
| Prothrombin time (s) | 11.0-13.7 | 14.80 | 14.4 | 13.1 |
| Activated partial thromboplastin time (s) | 31.5-43.5 | 32.30 | 38.9 | 34.6 |
| D-dimer (mg/L) | 0-0.55 | 7.71 | 4.77 | 0.27 |
| Antithrombin III (%) | 80-120 | 48 | - | 55 |
| Fibrinogen (g/L) | 2.0-4.0 | 3.09 | 4.87 | 3.09 |
| Protein C (%) | 70-140 | - | - | 89.3 |
| Protein S (%) | 75-130 | - | - | 90.4 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**